NanoVibronix signs $1.1M R&D deal with Veranex for next-gen UroShield, PainShield

ENvue Medical, Inc.

Entered into agreement with Veranex for R&D services for next-gen UroShield and PainShield; term ~50 weeks; fee up to ~$1.1M.
Fee payable monthly, due 45 days after invoice; late fee 1.5% per month; Veranex may suspend services if payment not made.
Either party may terminate on 60 days' notice; Veranex can also terminate for repeated late payments or relationship issues.
CEO Brian Murphy stated partnership aims to add therapeutic functionality and reduce cost of goods; press release dated March 28, 2024.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.85

ENvue Medical, Inc. entered into Agreement with Veranex, Inc. valued at approximately $1.1 million (effective 2024-03-22).

Action: entry
Counterparty: Veranex, Inc.
Value: approximately $1.1 million
Effective: 2024-03-22

Exact text from the filing

On March 22, 2024, NanoVibronix, Inc., a New York corporation, (the “Company”), entered into a standalone services agreement (the “Agreement”), by and between the Company and Veranex, Inc., a Delaware corporation

View on SEC.gov

481 material agreements filed in the last 30 days. Browse all material agreements →

ENvue Medical, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-011629

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.